Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Asfotase Alfa

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 2Strensiq

    02 7Strensiq

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Strensiq

    Asfotase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Strensiq

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Alexion

    Asfotase Alfa

    Main Therapeutic Indication : Metabolic Disorders

    Currency : USD

    2020 Revenue in Millions : 732

    2019 Revenue in Millions : 593

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Strensiq

    Asfotase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Strensiq

    United Kingdom
    arrow
    2024 ACI Convention
    Not Confirmed

    AstraZeneca

    Asfotase Alfa

    Main Therapeutic Indication : Metabolic Disorders

    Currency : USD

    2021 Revenue in Millions : 378

    2020 Revenue in Millions : 0

    Growth (%) : 100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Strensiq

    Asfotase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Strensiq

    United Kingdom
    arrow
    2024 ACI Convention
    Not Confirmed

    AstraZeneca

    Asfotase Alfa

    Main Therapeutic Indication : Metabolic Diseases

    Currency : USD

    2022 Revenue in Millions : 958

    2021 Revenue in Millions : 378

    Growth (%) : 153

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Strensiq

    Asfotase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Strensiq

    United Kingdom
    arrow
    2024 ACI Convention
    Not Confirmed

    AstraZeneca

    Asfotase Alfa

    Main Therapeutic Indication : Metabolic Diseases

    Currency : USD

    2023 Revenue in Millions : 1,152

    2022 Revenue in Millions : 958

    Growth (%) : 20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Strensiq

    Asfotase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Strensiq

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Alexion Pharmaceuticals

    Asfotase Alfa

    Main Therapeutic Indication : Bone Health

    Currency : USD

    2015 Revenue in Millions : 0

    2014 Revenue in Millions : 12

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Strensiq

    Asfotase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Strensiq

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Alexion

    Asfotase Alfa

    Main Therapeutic Indication : Metabolic Disorders

    Currency : USD

    2018 Revenue in Millions : 475

    2017 Revenue in Millions : 340

    Growth (%) : 40%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Strensiq

    Asfotase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Strensiq

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Alexion

    Asfotase Alfa

    Main Therapeutic Indication : Metabolic Disorders

    Currency : USD

    2016 Revenue in Millions : 210

    2015 Revenue in Millions : 12

    Growth (%) : 1,650

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Strensiq

    Asfotase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Strensiq

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Alexion

    Asfotase Alfa

    Main Therapeutic Indication : Metabolic Disorders

    Currency : USD

    2019 Revenue in Millions : 593

    2018 Revenue in Millions : 475

    Growth (%) : 25

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Strensiq

    Asfotase Alfa

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Strensiq

    U.S.A
    arrow
    2024 ACI Convention
    Not Confirmed

    Alexion

    Asfotase Alfa

    Main Therapeutic Indication : Metabolic Disorders

    Currency : USD

    2017 Revenue in Millions : 340

    2016 Revenue in Millions : 210

    Growth (%) : 62

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF